BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chavda VP, Prajapati R, Lathigara D, Nagar B, Kukadiya J, Redwan EM, Uversky VN, Kher MN, Rajvi P. Therapeutic monoclonal antibodies for COVID-19 management: an update. Expert Opin Biol Ther 2022. [PMID: 35604379 DOI: 10.1080/14712598.2022.2078160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang H, Hu T, Leng Y, de Lucio M, Gomez H. MPET(2): a multi-network poroelastic and transport theory for predicting absorption of monoclonal antibodies delivered by subcutaneous injection. Drug Deliv 2023;30:2163003. [PMID: 36625437 DOI: 10.1080/10717544.2022.2163003] [Reference Citation Analysis]
2 Zuo Y, Zheng Z, Huang Y, He J, Zang L, Ren T, Cao X, Miao Y, Yuan Y, Liu Y, Ma F, Dai J, Tian S, Ding Q, Zheng H. Vitamin C promotes ACE2 degradation and protects against SARS-CoV-2 infection. EMBO Rep 2023;:e56374. [PMID: 36876523 DOI: 10.15252/embr.202256374] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Tzitzi E, Pyrpasopoulou A, Kalmoukos P, Kefas A, Kyrana Z, Doukelis P, Varouktsi A, Imprialos K, Doumas M. Casivirimab/Imdevimab Effect on COVID-19 Outcome and Reinfection in a Real-World SARS-COV-2 Variant Transition Period Setting. Monoclon Antib Immunodiagn Immunother 2023;42:48-50. [PMID: 36757301 DOI: 10.1089/mab.2022.0033] [Reference Citation Analysis]
4 Venturas JP. HIV and COVID-19 Disease. Semin Respir Crit Care Med 2023;44:35-49. [PMID: 36646084 DOI: 10.1055/s-0042-1758852] [Reference Citation Analysis]
5 Torrini F, Battaglia F, Sestaioni D, Palladino P, Scarano S, Minunni M. Monoclonal antibodies (mAbs) optical detection by coupling innovative imprinted biopolymers and magnetic beads: the case of therapeutic mAb anti-myostatin detection. Sensors and Actuators B: Chemical 2023. [DOI: 10.1016/j.snb.2023.133586] [Reference Citation Analysis]
6 Meng L, Zha J, Zhou B, Cao L, Jiang C, Zhu Y, Li T, Lu L, Zhang J, Yang H, Feng J, Gu Z, Tang H, Jiang L, Li D, Lavillette D, Zhang X. A Spike-destructing human antibody effectively neutralizes Omicron-included SARS-CoV-2 variants with therapeutic efficacy. PLoS Pathog 2023;19:e1011085. [PMID: 36706160 DOI: 10.1371/journal.ppat.1011085] [Reference Citation Analysis]
7 Chavda VP, Balar P, Vaghela D, Solanki HK, Vaishnav A, Hala V, Vora L. Omicron Variant of SARS-CoV-2: An Indian Perspective of Vaccination and Management. Vaccines (Basel) 2023;11. [PMID: 36680006 DOI: 10.3390/vaccines11010160] [Reference Citation Analysis]
8 Zhaori G, Lu L, Liu C, Han S, Guo Y. Better design leads to better results – Importance of virological outcome design in clinical trials for antiviral treatment of coronavirus disease 2019. Pediatric Investigation 2023. [DOI: 10.1002/ped4.12363] [Reference Citation Analysis]
9 Amodio E, Genovese D, Fallucca A, Ferro P, Sparacia B, D'Azzo L, Fertitta A, Maida CM, Vitale F. Clinical Severity in Different Waves of SARS-CoV-2 Infection in Sicily: A Model of Smith's "Law of Declining Virulence" from Real-World Data. Viruses 2022;15. [PMID: 36680165 DOI: 10.3390/v15010125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Morgan MS, Yan K, Le TT, Johnston RA, Amarilla AA, Muller DA, McMillan CLD, Modhiran N, Watterson D, Potter JR, Sng JDJ, Lor M, Paramitha D, Isaacs A, Khromykh AA, Hall RA, Suhrbier A, Rawle DJ, Hobson-Peters J. Monoclonal Antibodies Specific for SARS-CoV-2 Spike Protein Suitable for Multiple Applications for Current Variants of Concern. Viruses 2022;15. [PMID: 36680179 DOI: 10.3390/v15010139] [Reference Citation Analysis]
11 Chavda VP, Soni S, Vora LK, Soni S, Khadela A, Ajabiya J. mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics. Vaccines (Basel) 2022;10. [PMID: 36560560 DOI: 10.3390/vaccines10122150] [Reference Citation Analysis]
12 Chavda VP, Ping FF, Chen ZS. An Impact of COVID-19 on Cancer Care: An Update. Vaccines (Basel) 2022;10. [PMID: 36560482 DOI: 10.3390/vaccines10122072] [Reference Citation Analysis]
13 Chavda VP, Patel AB, Vora LK, Singla RK, Shah P, Uversky VN, Apostolopoulos V. Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19. Curr Pharm Des 2022;28:3658-70. [PMID: 36284382 DOI: 10.2174/1381612829666221024124848] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mcdonnell S, Floyd Principe R, Soares Zamprognio M, Whelan J. Challenges and Emerging Technologies in Biomanufacturing of Monoclonal Antibodies (mAbs). Biomedical Engineering 2022. [DOI: 10.5772/intechopen.108565] [Reference Citation Analysis]
15 Chavda VP, Bezbaruah R, Deka K, Nongrang L, Kalita T. The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far. Vaccines 2022;10:1926. [DOI: 10.3390/vaccines10111926] [Reference Citation Analysis]
16 Esposito R, Mirra D, Sportiello L, Spaziano G, D’agostino B. Overview of Antiviral Drug Therapy for COVID-19: Where Do We Stand? Biomedicines 2022;10:2815. [DOI: 10.3390/biomedicines10112815] [Reference Citation Analysis]
17 Chavda VP, Yao Q, Vora LK, Apostolopoulos V, Patel CA, Bezbaruah R, Patel AB, Chen Z. Fast-track development of vaccines for SARS-CoV-2: The shots that saved the world. Front Immunol 2022;13:961198. [DOI: 10.3389/fimmu.2022.961198] [Reference Citation Analysis]
18 Chavda VP, Patel AB, Vora LK, Apostolopoulos V, Uhal BD. Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management. Expert Rev Vaccines 2022. [PMID: 35929957 DOI: 10.1080/14760584.2022.2110076] [Reference Citation Analysis]
19 Chavda VP, Chhabria MT, Apostolopoulos V. Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes. Biologics 2022;2:165-70. [DOI: 10.3390/biologics2030013] [Reference Citation Analysis]
20 Zuo Y, Zheng Z, Huang Y, He J, Zang L, Ren T, Cao X, Miao Y, Yuan Y, Liu Y, Ma F, Tian S, Dai J, Ding Q, Zheng H. Vitamin C is an efficient natural product for prevention of SARS-CoV-2 infection by targeting ACE2 in both cell and in vivo mouse models.. [DOI: 10.1101/2022.07.14.499651] [Reference Citation Analysis]
21 Chavda VP, Sonak SS, Munshi NK, Dhamade PN. Pseudoscience and fraudulent products for COVID-19 management. Environ Sci Pollut Res Int 2022. [PMID: 35836045 DOI: 10.1007/s11356-022-21967-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Chavda VP, Soni S, Prajapati R, Yallapu MM, Apostolopoulos V. Reply to the letter 'Effectiveness of COVID-19 vaccines against Omicron variant'. Immunotherapy 2022. [PMID: 35787091 DOI: 10.2217/imt-2022-0135] [Reference Citation Analysis]
23 Chavda VP, Vuppu S, Mishra T, Kamaraj S, Patel AB, Sharma N, Chen ZS. Recent review of COVID-19 management: diagnosis, treatment and vaccination. Pharmacol Rep 2022;74:1120-48. [PMID: 36214969 DOI: 10.1007/s43440-022-00425-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]